Opexa Therapeutics (ACER) Getting Somewhat Positive Media Coverage, Report Finds

Media headlines about Opexa Therapeutics (NASDAQ:ACER) have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Opexa Therapeutics earned a news impact score of 0.01 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 44.8538482483994 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Opexa Therapeutics (NASDAQ ACER) opened at $16.36 on Friday. Opexa Therapeutics has a 1-year low of $5.69 and a 1-year high of $22.63. The stock has a market cap of $116.48, a price-to-earnings ratio of -2.85 and a beta of 2.24.

Opexa Therapeutics (NASDAQ:ACER) last issued its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter. equities analysts anticipate that Opexa Therapeutics will post -1.48 earnings per share for the current year.

A number of brokerages have issued reports on ACER. ValuEngine raised shares of Opexa Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. HC Wainwright began coverage on shares of Opexa Therapeutics in a report on Wednesday, December 20th. They set a “buy” rating on the stock.

WARNING: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3126849/opexa-therapeutics-acer-getting-somewhat-positive-media-coverage-report-finds.html.

Opexa Therapeutics Company Profile

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Insider Buying and Selling by Quarter for Opexa Therapeutics (NASDAQ:ACER)

Receive News & Ratings for Opexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.